Comparing weight based and non-weight based norepinephrine dosing strategies

Background
- Norepinephrine is designated a high-alert medication by the Institute for Safe Medication Practices.
- There is currently little guidance on norepinephrine dosing. Pharmacy resources advise to titrate to lowest effective dose and state that institutional protocols may vary.
- Current literature has not identified a clear benefit of either weight based (WBD) or non-weight based dosing (Non-WBD).

Objective
- To quantify and compare the use of norepinephrine between dosing strategies

Methods
- Single-centered, IRB-approved, retrospective chart review
- Pre and post June 2018 protocol revision from non-WBD to WBD of norepinephrine

Inclusion criteria
- Critical care patients receiving norepinephrine as their initial vasopressor for >1 hour
- Pregnant or <18 years old
- Initial vasopressor other than norepinephrine
- Norepinephrine drip started at outside institution
- Second shock event in same admission
- Discrete and continuous data were analyzed with the Chi squared and Mann-Whitney U tests, respectively

Primary Outcome
- Assess differences in norepinephrine usage between the dosing strategies

Secondary Outcomes
- Initial, average, and maximum norepinephrine infusion rates
- Cumulative norepinephrine dose
- Use of second or third vasopressors

Results
- 69 patients were included, with 32 receiving non-WBD and 37 receiving WBD.

Discussion and Implications
- This study was limited by its small sample size and retrospective nature.
- Patients in the non-WBD group received higher infusion rates and cumulative doses of norepinephrine.
- Non-WBD patients were more severely ill at baseline and experienced increased mortality rates. This may limit the external validity of the study since sicker patients tend to require higher vasopressor doses.
- Future research will further assess the differences in severity of illness between the groups

INVESTIGATOR TEAM

Critical Care Collaborative
College of Pharmacy
UNIVERSITY OF GEORGIA

INVESTIGATOR TEAM
Peyton Moon, PharmD Candidate; Steven Castellanos, PharmD Candidate; Ansley Gayle, PharmD Candidate; Mary Ray, PharmD; Susan E Smith, PharmD, BCPS, BCCCP